Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

GHRP2 vs Ipamorelin: GH Secretagogue Comparison & Stacking

Back to library
peptide

GHRP2 vs Ipamorelin: GH Secretagogue Comparison & Stacking

9 min read
Comparison Study
GH Secretagogue Research
Clinical Evidence
Last Updated: May 2026

GHRP2 vs Ipamorelin is one of the most studied questions in GH secretagogue research — both compounds act on the ghrelin receptor (GHS-R1a) to stimulate growth hormone release, but their selectivity profiles, secondary hormonal effects, and research applications diverge significantly. GHRP-2 is a potent, broad-spectrum GHS-R1a agonist that also elevates cortisol, prolactin, and ACTH; Ipamorelin is a more selective pentapeptide that produces robust GH release with minimal off-target hormonal activity. When studied alongside GHRH analogues such as CJC-1295+DAC, both show synergistic GH amplification via dual-pathway pituitary activation.

Key Takeaways

  • Both GHRP-2 and Ipamorelin activate GHS-R1a to stimulate pituitary GH release — but Ipamorelin does so with significantly greater hormonal selectivity
  • GHRP-2 elevates cortisol, ACTH, and prolactin alongside GH; Ipamorelin demonstrates negligible impact on these hormones at research doses (Raun et al. 1998)
  • Ipamorelin is a pentapeptide (5 amino acids); GHRP-2 is a hexapeptide (6 amino acids) — the structural difference underlies their different receptor interaction profiles
  • Both compounds produce synergistic GH release when combined with GHRH-R agonists such as CJC-1295 — dual-pathway activation amplifies GH output substantially
  • Both are available as research chemicals in the UK; neither is a controlled substance under MDA 1971 or the Psychoactive Substances Act 2016
6 vs 5
Amino acids: GHRP-2 (hexapeptide) vs Ipamorelin (pentapeptide)
~0
Cortisol/ACTH elevation with Ipamorelin vs significant increase with GHRP-2 (Raun 1998)
3–10×
GH amplification when GHS + GHRH analog combined vs single compound (research literature)
1998
Year Ipamorelin’s selectivity vs GHRP-6 first characterised by Raun et al. (Eur J Endocrinol)

Both Compounds Available at Pure Grade Labs

GHRP-2 and Ipamorelin — 10MG vials, 99%+ purity, batch-specific COA. UK research supply.

Browse Research Compounds →

Mechanism of Action: How GHRP-2 and Ipamorelin Work

Both GHRP-2 and Ipamorelin are growth hormone secretagogues (GHS) — synthetic peptides that stimulate GH release from the anterior pituitary by activating the ghrelin receptor, formally designated GHS-R1a (Growth Hormone Secretagogue Receptor type 1a). GHS-R1a is a GPCR expressed on somatotroph cells in the pituitary and on neurons in the arcuate nucleus of the hypothalamus. Ligand binding activates Gq/11 signalling pathways, elevating intracellular calcium and triggering GH secretory granule release.

The GHS-R1a pathway is mechanistically distinct from the GHRH receptor (GHRH-R) pathway activated by GHRH analogues such as CJC-1295. Both pathways converge on GH release at the pituitary level, but through different second-messenger cascades (Gq/calcium for GHS-R1a vs Gs/cAMP for GHRH-R). This mechanistic orthogonality is why combining a GHS-R1a agonist with a GHRH-R agonist produces synergistic rather than simply additive GH release — both signalling axes are maximally engaged simultaneously.

Where GHRP-2 and Ipamorelin Diverge

Despite sharing the same primary target (GHS-R1a), GHRP-2 and Ipamorelin demonstrate markedly different selectivity profiles in published research. GHRP-2 (His-D-2Nal-D-Phe-Lys-NH2 backbone) activates GHS-R1a with high potency but also interacts with additional receptors or pathways that trigger corticotroph and lactotroph activity at the pituitary — resulting in measurable elevations in ACTH, cortisol, and prolactin alongside GH. This is not a side effect in the conventional pharmacological sense; it is an on-target effect of GHRP-2’s receptor interaction profile.

Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2), developed to improve upon the selectivity limitations of earlier GHS compounds, was characterised in landmark research by Raun et al. (1998) as producing robust GH release without significant ACTH, cortisol, or prolactin elevation. This selectivity is attributed to subtly different receptor engagement geometry arising from the N-terminal Aib (α-aminoisobutyric acid) substitution, which appears to reduce off-target pituitary receptor interactions while preserving GHS-R1a binding affinity.

A research team studying isolated GH axis activation needed to determine whether observed downstream effects in their model were attributable specifically to GH or to broader corticotroph co-stimulation. Switching from GHRP-2 to Ipamorelin as their primary GHS — which produced equivalent GH elevation with negligible ACTH or cortisol changes — allowed them to isolate the GH-specific signal from the confounding influence of HPA axis co-activation. The selectivity difference between two closely related compounds changed the interpretability of the entire dataset.

GHRP-2 vs Ipamorelin: Head-to-Head Comparison

Parameter GHRP-2 Ipamorelin
Structure Hexapeptide (6 amino acids) Pentapeptide (5 amino acids)
Primary receptor GHS-R1a (high affinity) GHS-R1a (high affinity)
GH release Robust Robust
Cortisol elevation Yes — significant in research models Negligible (Raun et al. 1998)
ACTH elevation Yes Negligible
Prolactin elevation Yes Negligible
Ghrelin-like hunger effect Yes — GHS-R1a in hypothalamus Minimal in research models
Molecular weight 817 Da 711 Da
Research selectivity profile Broad (GH + HPA axis) Narrow (GH-selective)
Synergy with CJC-1295 Yes — dual pathway Yes — dual pathway

Dual-Pathway GH Research: Stacking with CJC-1295

The most significant research application of both GHRP-2 and Ipamorelin is their combination with GHRH analogues — specifically CJC-1295+DAC — to achieve maximal GH axis activation via simultaneous GHRH-R and GHS-R1a engagement. The physiological rationale is well-established: endogenous GH pulsatility is driven by the simultaneous rhythmic release of GHRH (stimulatory, via GHRH-R) and ghrelin (stimulatory, via GHS-R1a), counterbalanced by somatostatin (inhibitory). Exogenous replication of this dual-agonist model produces substantially larger GH pulses than either axis alone.

The published literature consistently demonstrates 3–10-fold amplification of GH release when a GHRH analogue and a GHS are co-administered compared to either compound administered alone at equivalent concentrations. This synergistic amplification is the mechanistic basis for the GH Optimization Research Stack used in two-pathway GH axis research.

Which to Pair with CJC-1295: GHRP-2 or Ipamorelin?

The research question determines the compound selection. When the objective is to characterise maximal GH axis stimulation without regard to secondary hormonal effects, either compound produces equivalent synergistic amplification with CJC-1295. When the research objective requires isolation of GH-specific effects — distinguishing GH-mediated outcomes from cortisol- or ACTH-mediated effects in the same model — Ipamorelin’s selectivity profile makes it the methodologically cleaner choice. GHRP-2’s broader hormonal profile is itself a research tool in studies that require simultaneous HPA axis and GH axis activation.

GH Optimisation Research Stack

GHRP-2 + CJC-1295+DAC — the dual-pathway GH axis research combination. Pure Grade Labs standard.

View GH Research Stack →

Key Research Studies

Raun et al. 1998 — Ipamorelin Selectivity Characterisation

This foundational paper characterised Ipamorelin as a potent GH secretagogue with a unique selectivity profile relative to GHRP-2 and GHRP-6. In pig and rat models, Ipamorelin produced GH release comparable in magnitude to GHRP-6 but with no significant elevation of ACTH or cortisol — a profile GHRP-6 and GHRP-2 do not share. The researchers identified the N-terminal Aib modification as the structural feature conferring this selectivity and proposed Ipamorelin as a tool compound for studying pure GH-secretion biology without confounding HPA axis co-stimulation.

Bowers et al. — GHRP-2 Original Characterisation

GHRP-2 was originally characterised by Cyril Bowers and colleagues as a potent, full-efficacy GHS-R1a agonist with robust GH-releasing activity across rodent, primate, and human models. The GH response to GHRP-2 was demonstrated to be dose-dependent, blunted by somatostatin, and amplified by co-administration of GHRH — establishing the mechanistic groundwork for combination GHS + GHRH research. GHRP-2 became the reference GHS compound against which newer secretagogues including Ipamorelin were benchmarked.

Frequently Asked Questions

Is GHRP-2 or Ipamorelin more potent for GH release?

Published research demonstrates broadly comparable GH release magnitudes between GHRP-2 and Ipamorelin at equivalent research concentrations. The primary differentiator is not potency but selectivity. GHRP-2 activates cortisol, ACTH, and prolactin pathways alongside GH; Ipamorelin does not. For pure GH research, Ipamorelin’s selectivity represents a methodological advantage. For studies requiring simultaneous GH and HPA axis activation, GHRP-2 is the appropriate tool compound.

Can GHRP-2 and Ipamorelin be studied together?

Research combining GHRP-2 and Ipamorelin is uncommon in the published literature because both compounds act on the same receptor (GHS-R1a), making combinatorial synergy unlikely at that level. The standard dual-pathway research model pairs either GHS compound with a GHRH-R agonist (CJC-1295, Mod GRF), not two GHS-R1a agonists together. Combining GHRP-2 and Ipamorelin would be expected to produce partial agonist competition or simple additive effects at the same receptor, not the synergy observed with the GHS + GHRH combination.

Why does GHRP-2 raise cortisol but Ipamorelin does not?

The structural difference at the N-terminus — GHRP-2 has a D-2-naphthylalanine where Ipamorelin has an Aib (α-aminoisobutyric acid) — appears to produce subtle differences in receptor engagement geometry at GHS-R1a on corticotroph cells. GHRP-2 activates GHS-R1a across both somatotroph (GH-releasing) and corticotroph (ACTH-releasing) cell populations; Ipamorelin’s binding profile preferentially engages somatotroph GHS-R1a with minimal corticotroph activation. The precise molecular mechanism remains an active area of receptor pharmacology research.

What does stacking with CJC-1295 add to the research model?

CJC-1295+DAC acts on GHRH-R, a completely different receptor and second-messenger cascade from GHS-R1a. When administered alongside a GHS such as GHRP-2 or Ipamorelin, GHRH-R and GHS-R1a are both maximally engaged, producing synergistic GH amplification — documented at 3–10 times the output of either compound alone. This dual-axis model more closely replicates the physiological mechanism of endogenous GH pulsatility, which is driven by simultaneous hypothalamic GHRH and ghrelin release.

Are GHRP-2 and Ipamorelin legal in the UK?

Both GHRP-2 and Ipamorelin are not listed as controlled substances under the Misuse of Drugs Act 1971. They are available as research chemicals in the UK for laboratory research purposes only. Neither compound is MHRA-approved for human therapeutic use and must not be used for human consumption. Researchers should verify applicable local regulations before ordering.

Source GHRP-2 and Ipamorelin for Research

10MG vials. 99%+ purity HPLC verified. Batch COA with every order. Rapid UK dispatch.

View All Research Compounds →

Summary

The GHRP2 vs Ipamorelin comparison resolves into a question of research objective rather than raw potency. Both compounds are GHS-R1a agonists that produce robust GH release; both synergise with GHRH analogues via dual-pathway pituitary activation; and both are established tools in GH axis research. The meaningful distinction is hormonal selectivity: GHRP-2 co-activates cortisol, ACTH, and prolactin pathways, while Ipamorelin produces GH release in relative isolation from these secondary hormonal effects.

For research requiring clean GH-specific signal isolation, Ipamorelin is the methodologically superior tool. For research modelling broad GH axis + HPA axis co-stimulation, GHRP-2’s wider hormonal profile becomes a research asset. The dual-pathway combination with CJC-1295+DAC remains the standard model for maximal, physiologically-patterned GH axis activation regardless of which GHS-R1a compound is selected.

Both compounds are available in the UK as research chemicals, with a clear regulatory position under MDA 1971 — neither is classified as a controlled substance. Research purity standards of 99%+ HPLC with batch-specific COA remain the benchmark for assay-quality material.

References

  1. Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 139(5):552–561. DOI: 10.1530/eje.0.1390552
  2. Bowers CY, et al. (1991). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 114(5):1537–1545.
  3. Petersenn S, et al. (1999). Structure and regulation of the human growth hormone-secretagogue receptor. Endocrinology. 140(9):4152–4165.
  4. Howard AD, et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 273(5277):974–977.
  5. Jette L, et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology. 146(7):3052–3058.
Disclaimer: This article is for research and informational purposes only. GHRP-2 and Ipamorelin are not MHRA-approved and are not intended for human consumption. Research-grade compounds from Pure Grade Labs are sold for in vitro and preclinical laboratory research purposes only. This content does not constitute medical advice.